Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
16000 studies found for:    Canada
Show Display Options
Rank Status Study
1 Recruiting Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness
Condition: Hidradenitis Suppurativa (HS)
2 Completed APPROACH Study: Quality of Life and Outcomes Assessment in Participants With Chronic Hepatitis C (CHC) Treated With Pegylated Interferon (PEG-IFN) Alfa-2a and Ribavirin
Condition: Hepatitis C, Chronic
Interventions: Drug: Pegylated interferon (PEG-INF) alfa-2a;   Drug: Ribavirin
3 Completed Persistence With Prolia® (Denosumab) in Postmenopausal Women With Osteoporosis
Condition: Osteoporosis, Age-Related
4 Recruiting An Observational Study to Assess the Canagliflozin Treatment in Type 2 Diabetes Mellitus in a Usual Clinical Practice in Canada
Condition: Diabetes Mellitus, Type 2
Intervention: Other: No Intervention
5 Recruiting A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel
Condition: Acne Vulgaris
Interventions: Drug: XPF-005;   Drug: Placebo
6 Recruiting Study Comparing Two Different Schedules of Palbociclib Plus Second Line Endocrine Therapy in Women With Estrogen Receptor Positive, HER2 Negative Advanced/Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Palbociclib 100mg;   Drug: Palbociclib 125mg;   Drug: Fulvestrant or Tamoxifen or Aromatase Inhibitor
7 Recruiting Post-Marketing Use Of Inflectra (Infliximab) For Standard Of Care Treatment Of Rheumatoid Disease Who Are Naïve To Biologics Or Switched From Remicade™
Conditions: Rheumatoid Arthritis;   Ankylosing Spondylitis;   Psoriatic Arthritis
Intervention: Drug: Infliximab (Inflectra™)
8 Recruiting Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease
Condition: Crohn Disease
Interventions: Drug: GED-0301;   Drug: Placebo
9 Recruiting Effectiveness of Paritaprevir/r - Ombitasvir, ± Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C in Canada
Condition: Chronic Hepatitis C
10 Recruiting Standard vs. Accelerated Initiation of RRT in Acute Kidney Injury (STARRT-AKI: Principal Trial)
Condition: Acute Kidney Injury
Interventions: Other: Standard RRT initiation;   Other: Accelerated RRT initiation
11 Recruiting Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada
Condition: Idiopathic Pulmonary Fibrosis
Intervention: Other: No intervention
12 Recruiting Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease
Condition: Diabetic Kidney Disease
Interventions: Drug: Finerenone (BAY94-8862);   Drug: Placebo
13 Recruiting Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease
Condition: Diabetic Kidney Disease
Interventions: Drug: Finerenone (BAY94-8862);   Drug: Placebo
14 Recruiting Effect of Dalcetrapib vs Placebo on CV Risk in a Genetically Defined Population With a Recent ACS
Condition: Acute Coronary Syndrome
Interventions: Drug: dalcetrapib;   Drug: Placebo
15 Recruiting Impact of Adalimumab on Patient-reported Outcomes in Ulcerative Colitis
Condition: Ulcerative Colitis
16 Recruiting Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities
Condition: Peripheral Artery Disease
Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
17 Recruiting A Pragmatic Trial of Ambulatory Toxicity Management in Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Early Stage Breast Cancer
Condition: Early Stage Breast Cancer
Interventions: Other: Proactive Telephone Toxicity Management;   Other: Control Arm;   Other: PRO Sub-Study
18 Recruiting Safety, Tolerability, and Effect of Alirocumab in High Cardiovascular Risk Patients With Severe Hypercholesterolemia Not Adequately Controlled With Conventional Lipid-modifying Therapies (ODYSSEY APPRISE)
Condition: Hypercholesterolemia
Interventions: Drug: ALIROCUMAB SAR236553 (REGN727);   Drug: placebo (for injection training only)
19 Recruiting Effect of Albiglutide, When Added to Standard Blood Glucose Lowering Therapies, on Major Cardiovascular Events in Subjects With Type 2 Diabetes Mellitus
Condition: Diabetes Mellitus
Interventions: Biological: Albiglutide 30 mg;   Biological: Albiglutide 50 mg;   Biological: Albiglutide matching placebo
20 Recruiting Probiotics to Prevent Severe Pneumonia and Endotracheal Colonization Trial
Conditions: Ventilator Associated Pneumonia;   Infections;   C-Difficile;   Antibiotic-associated Diarrhea;   Diarrhea
Interventions: Drug: L. rhamnosus GG - Probiotic;   Drug: Placebo - Microcrystalline Cellulose

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years